<DOC>
	<DOC>NCT02696798</DOC>
	<brief_summary>The main purpose of this study is to evaluate the efficacy and safety of ixekizumab in tumor necrosis factor (TNF) inhibitor-experienced participants with radiographic axial spondyloarthritis (rad-axSpA).</brief_summary>
	<brief_title>A Study of Ixekizumab (LY2439821) in TNF Inhibitor Experienced Participants With Radiographic Axial Spondyloarthritis</brief_title>
	<detailed_description />
	<mesh_term>Spondylarthritis</mesh_term>
	<criteria>Are ambulatory. Have an established diagnosis of radiographic axial spondyloarthritis (radxSpA) with sacroiliitis defined radiographically according to the modified New York criteria. Participants have a history of back pain â‰¥3 months with age at onset &lt;45 years. Have had prior treatment with at least 1 and not more than 2 TNF inhibitors. Must have had an inadequate response to 2 or more NSAIDs at the therapeutic dose range for a total duration of at least 4 weeks OR have a history of intolerance to NSAIDs. Have a history of prior therapy for axSpa for at least 12 weeks prior to screening. Have total ankylosis of the spine. Have never taken a TNF inhibitor medication or have taken more than 2. Have recently received a live vaccine within 12 weeks or have had a vaccination with Bacillus CalmetteGuerin (BCG) within the past year. Have an ongoing or serious infection within the last 12 weeks or evidence of active tuberculosis. Have a compromised immune system. Have any other serious and/or uncontrolled diseases. Have either a current diagnosis or a recent history of malignant disease. Have had major surgery within 8 weeks of baseline, or will require surgery during the study. Are pregnant or breastfeeding.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Ankylosing Spondylitis</keyword>
</DOC>